PL2496596T3 - Peptydy terapeutyczne - Google Patents

Peptydy terapeutyczne

Info

Publication number
PL2496596T3
PL2496596T3 PL10784830T PL10784830T PL2496596T3 PL 2496596 T3 PL2496596 T3 PL 2496596T3 PL 10784830 T PL10784830 T PL 10784830T PL 10784830 T PL10784830 T PL 10784830T PL 2496596 T3 PL2496596 T3 PL 2496596T3
Authority
PL
Poland
Prior art keywords
therapeutic peptides
peptides
therapeutic
Prior art date
Application number
PL10784830T
Other languages
English (en)
Inventor
Morten Strøm
Terkel Hansen
Martina Havelkova
Veronika Tørfoss
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of PL2496596T3 publication Critical patent/PL2496596T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10784830T 2009-11-02 2010-11-02 Peptydy terapeutyczne PL2496596T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds
EP10784830.1A EP2496596B1 (en) 2009-11-02 2010-11-02 Therapeutic peptides

Publications (1)

Publication Number Publication Date
PL2496596T3 true PL2496596T3 (pl) 2017-08-31

Family

ID=41435032

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10784830T PL2496596T3 (pl) 2009-11-02 2010-11-02 Peptydy terapeutyczne

Country Status (15)

Country Link
US (1) US8809280B2 (pl)
EP (1) EP2496596B1 (pl)
JP (1) JP5810090B2 (pl)
KR (1) KR101730680B1 (pl)
CN (1) CN102762586B (pl)
AU (1) AU2010311186B2 (pl)
BR (1) BR112012010333A2 (pl)
CA (1) CA2777749C (pl)
DK (1) DK2496596T3 (pl)
ES (1) ES2621188T3 (pl)
GB (1) GB0919194D0 (pl)
NZ (1) NZ599791A (pl)
PL (1) PL2496596T3 (pl)
RU (2) RU2548905C2 (pl)
WO (1) WO2011051692A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3974563A1 (en) 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides
JP7020910B2 (ja) 2015-03-13 2022-02-16 中外製薬株式会社 改変アミノアシルtRNA合成酵素およびその用途
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN109071600A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体(aspd)结合抑制肽以及评价和筛选方法
WO2018143145A1 (ja) 2017-01-31 2018-08-09 中外製薬株式会社 無細胞翻訳系におけるペプチドの合成方法
GB201705255D0 (en) * 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds
WO2018188761A1 (en) 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
US11542299B2 (en) 2017-06-09 2023-01-03 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptide containing N-substituted amino acid
JP7411414B2 (ja) 2017-12-15 2024-01-11 中外製薬株式会社 ペプチドの製造方法、及び塩基の処理方法
KR20250119653A (ko) 2018-11-07 2025-08-07 추가이 세이야쿠 가부시키가이샤 O-치환 세린 유도체의 제조 방법
EP3889164A4 (en) 2018-11-30 2022-11-02 Chugai Seiyaku Kabushiki Kaisha METHOD FOR DEPROTECTION AND METHOD FOR RESIN REMOVAL IN A SOLID PHASE REACTION OF A PEPTIDE COMPOUND OR AN AMIDE COMPOUND, AND METHOD FOR PRODUCTION OF A PEPTIDE COMPOUND
JP7472101B2 (ja) 2019-03-15 2024-04-22 中外製薬株式会社 芳香族アミノ酸誘導体の製造方法
CN110294793B (zh) * 2019-06-24 2023-10-27 合肥科生景肽生物科技有限公司 Sumo荧光探针及其制备方法
JP6880352B1 (ja) 2019-11-07 2021-06-02 中外製薬株式会社 Kras阻害作用を有する環状ペプチド化合物
CN114790151B (zh) * 2022-02-14 2023-03-31 湖南省湘中制药有限公司 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法
KR20250122523A (ko) 2022-12-20 2025-08-13 리틱스 바이오파마 에이에스 종양 용해성 펩티드 및 키토산을 포함하는 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342705A (en) 1979-11-23 1982-08-03 Monsanto Company Methylene thioethers
AU565221B2 (en) 1982-06-03 1987-09-10 Montedison S.P.A. 2-(1,2,4-triazol-1-yl) propanone derivatives
IT1161927B (it) 1983-03-31 1987-03-18 Montedison Spa Furano-derivati ad attivita' fungicida
DK523288A (da) 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
CA2088195A1 (en) 1990-08-31 1992-03-01 David C. Horwell Cholecystokinin antagonists, their preparation and therapeutic use
US5593967A (en) 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5885782A (en) 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
CZ297544B6 (cs) 1996-01-02 2007-02-07 Aventis Pharmaceuticals Inc. Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
DE102006018080A1 (de) 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
JP5322108B2 (ja) * 2006-07-10 2013-10-23 ペーベーアードライ ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗菌ペプチド
GB0724951D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
ATE482186T1 (de) * 2008-03-18 2010-10-15 Univ Dresden Tech Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion

Also Published As

Publication number Publication date
DK2496596T3 (en) 2017-04-03
EP2496596A1 (en) 2012-09-12
JP2013509389A (ja) 2013-03-14
CA2777749C (en) 2019-08-06
ES2621188T3 (es) 2017-07-03
GB0919194D0 (en) 2009-12-16
JP5810090B2 (ja) 2015-11-11
RU2015111706A3 (pl) 2018-10-29
RU2548905C2 (ru) 2015-04-20
US20130035296A1 (en) 2013-02-07
KR20120104986A (ko) 2012-09-24
BR112012010333A2 (pt) 2016-03-29
AU2010311186B2 (en) 2015-09-24
RU2676713C2 (ru) 2019-01-10
RU2012121264A (ru) 2013-12-10
WO2011051692A1 (en) 2011-05-05
CN102762586A (zh) 2012-10-31
CN102762586B (zh) 2016-10-05
AU2010311186A1 (en) 2012-05-31
US8809280B2 (en) 2014-08-19
KR101730680B1 (ko) 2017-04-26
NZ599791A (en) 2014-10-31
RU2015111706A (ru) 2015-11-10
EP2496596B1 (en) 2017-01-11
CA2777749A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
PL2496596T3 (pl) Peptydy terapeutyczne
GB0908957D0 (en) Therapeutic agents
ZA201102822B (en) Therapeutic antiviral peptides
EP2605786A4 (en) THERAPEUTIC PEPTIDES
GB201012651D0 (en) Peptides
IL214257A0 (en) Peptides for vaccine
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0916997D0 (en) Combination therapy
GB0907973D0 (en) Combination therapy
GB0910493D0 (en) Therapeutic agents
GB0906026D0 (en) Therapeutic compounds
GB0911790D0 (en) Peptides
IL214496A0 (en) Short b-defensin-derived peptides
GB0921430D0 (en) Protein for therapeutic use
GB0922098D0 (en) Therapeutic use
GB0903319D0 (en) Therapy
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903321D0 (en) Therapy
GB0919113D0 (en) Therapeutic invention
GB0919824D0 (en) Therapeutic agents
GB0903949D0 (en) Therapeutic agents
GB0914533D0 (en) Therapeutic agents